Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer

被引:1
|
作者
Tang, Tao [1 ,2 ]
Zhi, Jingtai [3 ]
Zhang, Wei [1 ]
Hu, Linfei [1 ]
Ruan, Xianhui [1 ]
Chen, Xiaoyu [1 ]
Wang, Zhaohui [4 ]
Zheng, Xiangqian [1 ]
Gao, Ming [1 ,5 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Tumor, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China
[2] North Sichuan Med Coll, Inst Hepato Biliary Pancreat Intestinal Dis, Dept Hepatobiliary Surg 1, Affiliated Hosp, Nanchong, Peoples R China
[3] Tianjin First Cent Hosp, Dept Otolaryngol Head & Neck Surg, Tianjin, Peoples R China
[4] Univ Elect Sci & Technol China, Sch Med, Dept Head & Neck Surg, Sichuan Canc Hosp & Inst,Sichuan Canc Ctr, Chengdu, Peoples R China
[5] Tianjin Union Med Ctr, Dept Breast & Thyroid Surg, Tianjin, Peoples R China
关键词
PAPILLARY; SURVIVAL; ASSOCIATION; MANAGEMENT;
D O I
10.1155/2022/4348396
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: The purpose of the current study was to determine whether older patients with differentiated thyroid cancer (DTC) who received surgical treatment had a better cause-specific survival (CSS) than patients who were recommended surgery, but declined, and whether patients who underwent postoperative RAI-131 therapy had an impact on CSS based on TNM staging and number of lymph node metastases for all total or near-total thyroidectomy patients. Patients and Methods: This retrospective, population-based study analyzed the clinical data of 162 DTC patients from signal institution in China and 26,487 cases from the Surveillance, Epidemiology, and End Results (SEER) program registry. The patients were divided into two groups (underwent surgery and surgery recommended, but not performed) in the SEER cohort. Furthermore, patients were grouped as follows: T4; N1b; M1; T1-3N0-1a; specific number of lymph node metastases; and total or near-total thyroidectomy. Results: The 120-month cause-specific survival (CSS) rate of women and men showed a gradual declining trend from 60-64 to >= 80years of age in the group that underwent surgery. The CSS rate of women and men showed a marked downward and irregular trend with an increase in age in the recommended, but no surgery group in the SEER cohort. Univariate analysis indicated that the surgery group had a higher 120-month CSS in women in most stages and men, compared with the no surgery group in the SEER cohort. The analysis of the SEER cohort showed that RAI-131 therapy was associated with an improved 80-month CSS in T4/N1b/M1 women (P<0.0183) and men (P<0.0011). However, there were no CSS differences between the RAI-131 therapy and the no-RAI-131 group for the patients with T4/N1b/M1 (AJCC 7th) thyroid cancer in the Chinese cohort. There was no CSS difference in women or men between the T1-3N0 and T1-3N1a patients in the SEER cohort. And similar findings were observed in T1-3N1a patients in the Chinese cohort. There was no statistical difference between the two subgroups. Conclusions: Surgical treatment should be recommended for elderly DTC patients because surgery can lead to a better CSS. High-risk patients achieve a higher benefit-to-risk ratio with RAI-131 therapy. To avoid the adverse effects associated with RAI-131 therapy, a multidisciplinary discussion should be arranged for intermediate- and low-risk patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis
    Lin, Jen-Der
    Kuo, Sheng-Fong
    Huang, Bie-Yui
    Lin, Shu-Fu
    Chen, Szu-Tah
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1091 - 1096
  • [22] Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer
    Worden, Francis
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (06) : 267 - 279
  • [23] Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines
    Sia, Yi
    Dave, Rajiv, V
    Nour, Daniel
    Miller, Julie A.
    Skandarajah, Anita R.
    Tasevski, Robert
    ANZ JOURNAL OF SURGERY, 2019, 89 (11) : E502 - E506
  • [24] Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer
    Volpe, Fabio
    Nappi, Carmela
    Zampella, Emilia
    Di Donna, Erica
    Maurea, Simone
    Cuocolo, Alberto
    Klain, Michele
    CURRENT ONCOLOGY, 2024, 31 (07) : 3870 - 3884
  • [25] Clinico-social factors to choose radioactive iodine dose in differentiated thyroid cancer patients: an Asian survey
    Jabin, Zeenat
    Kwon, Seong Young
    Bom, Hee-Seung
    Lin, Yansong
    Yang, Ke
    Inaki, Anri
    Dewi, Ayu Rosemeilia
    Al-Ibraheem, Akram N.
    Al Balooshi, Batool
    San Luis, Teofilo O. L., Jr.
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (04) : 283 - 289
  • [26] Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer
    Lubitz, Carrie C.
    Kiernan, Colleen M.
    Toumi, Asmae
    Zhan, Tiannan
    Roth, Mara Y.
    Sosa, Julie A.
    Tuttle, R. Michael
    Grubbs, Elizabeth G.
    ENDOCRINE PRACTICE, 2021, 27 (05) : 383 - 389
  • [27] Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer
    Slonimsky, Einat
    Tulchinsky, Mark
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (31) : 3812 - 3827
  • [28] Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
    Jeong, Eugene
    Yoon, Joon-Kee
    Lee, Su Jin
    Soh, Euy Young
    Lee, Jeonghun
    An, Young-Sil
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 714 - 718
  • [29] Impact on Overall Survival of Radioactive Iodine in Low-Risk Differentiated Thyroid Cancer Patients
    Schvartz, Claire
    Bonnetain, Franck
    Dabakuyo, Sandrine
    Gauthier, Melanie
    Cueff, Adele
    Fieffe, Sandrine
    Pochart, Jean-Marie
    Cochet, Inna
    Crevisy, Elodie
    Dalac, Audrey
    Papathanassiou, Dimitri
    Toubeau, Michel
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (05) : 1526 - 1535
  • [30] Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients
    Mei, Xiaoran
    Yao, Xiaoqin
    Feng, Fang
    Cheng, Weiwei
    Wang, Hui
    BMC CANCER, 2021, 21 (01)